The Prescription Pattern of Chinese Herbal Products Containing Ginseng among Tamoxifen-Treated Female Breast Cancer Survivors in Taiwan: A Population-Based Study
Table 6
Number of new cases, population at risk, estimated hazard ratios (HR), and 95% confidence intervals (CI) estimated using the multivariate Cox’s regression model for a random sample from the National Health Insurance Research Database that included tamoxifen users stratified by age who were followed up from 1999 to 2008.
TMX use at baseline
TMX users using Chinese medicine containing Ginseng aged 55 to 79 years
TMX users not using Chinese medicine aged 55 to 79 years
Number of cases/person-years
Adjusted HR* (95% CI)
Number of cases/person-years
Adjusted HR* (95% CI)
Duration of TMX treatment
<2 years
10/10,379
1
33/15,576
1
2–4 years
12/7,396
6.03 (0.72–50.62)
11/6,370
1.13 (0.12–10.66)
>4 years
8/7,431
2.68 (0.18–40.90)
3/5,736
0.67 (0.02–19.90)
Cumulative TMX doses
<7,500 mg
7/6,293
1
26/10,695
1
7,500–14,999 mg
4/4,051
0.72 (0.19–2.81)
7/4,868
0.55 (0.24–1.28)
15,000–29,999 mg
10/7,335
0.22 (0.02–2.25)
11/6,270
0.65 (0.07–6.34)
≥30,000 mg
9/7,527
0.35 (0.02–5.60)
3/5,848
0.34 (0.01–10.36)
Adjusted for age at breast cancer diagnosis, insured salary, insured region, diabetes and hypertension, duration of TMX treatment, and cumulative TMX doses. TMX refers to tamoxifen.
